权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of HTP Assay for Inhibitors of Aerobactin Production

Aerobactin 生产抑制剂的 HTP 检测方法的开发

基本信息

批准号：
9101161
负责人：
ANDREW M GULICK
金额：
$ 48.26万
依托单位：
HAUPTMAN-WOODWARD MEDICAL RESEARCH INST
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-02-01 至 2019-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9101161
关键词：
Address Adopted Amikacin Aminoglycoside resistance Anabolism Antibiotic Resistance Antibiotics Antimicrobial Resistance Appearance Area Asia Asians Bacillus (bacterium)Bacteria Biochemical Biochemistry Biological Assay Biosynthetic Proteins Carbapenems Cells China Citrates Clinical Clinical Microbiology Community-Acquired Infections Data Development Disease Outbreaks Drug Targeting Drug resistance Endophthalmitis Enzymes Europe Exhibits Extended-spectrum β-lactamase FDA approved Frequencies Gram-Negative Bacteria Growth Healthcare Hospitals Human Hydroxylysine Incidence Individual Infection Iron Klebsiella pneumonia bacterium Left Libraries Life Ligase Liver Abscess Long-Term Care Meningitis Modeling Multi-Drug Resistance Mus Natural Products Necrotizing fasciitis North America Nosocomial Infections Organ Patients Pharmaceutical Preparations Phenotype Physical condensation Pilot Projects Plasmids Play Pneumonia Production Pyogenic Liver Abscess Quinolones Recording of previous events Reporting Resistance Retrospective Studies Role Series Siderophores Specificity Testing Tissues Travel United States National Institutes of Health Virulence Virulent aerobactin antimicrobial beta-Lactams capsule carbapenemase combat high risk high throughput screening hydroxamate in vivo inhibitor/antagonist miniaturize mortality mutant novel therapeutics pathogen public health relevance resistance frequency screening single molecule small molecule small molecule inhibitor small molecule libraries

项目摘要

DESCRIPTION (provided by applicant): A hypervirulent strain of Klebsiella pneumonia (hvKP) has recently been identified that causes life-threatening community-acquired infections in otherwise healthy individuals. Infections with this strain often begin with liver abscess and have the ability to spread metastatically to other organs. Originally identified in the Pacific Rim, incidence in the US is rising. The transfer of antibiotic resistance from classical strains of K. pneumonia to this hypervirulent strain, which has been experimentally demonstrated, raises the possibility of a resistant, hypervirulent strain and motivates our efforts to identify alternate antibiotic strategies. The phenotype of this hvKP strain includes higher capsule expression, resulting in a hypermucoviscous appearance, and increased production of iron acquisition factors. Specifically, the hvKP strains produce aerobactin, a hydroxamate siderophore that allows the bacteria to grow in low-iron conditions. We have demonstrated in mouse infection models that this aerobactin expression is responsible for virulence. We therefore propose to develop a high-throughput screen to identify small molecule inhibitors of aerobactin production. The collaborative team of Drs. Gulick and Russo brings expertise in all areas of clinical microbiology, biochemistry of natural product biosynthesis, and inhibitor development. We have adopted a two- pronged approach in which we will simultaneously develop a high-throughput biochemical screen for inhibitors of one of the aerobactin biosynthetic proteins as well as a phenotypic screen with live cells to identify in vivo-active compounds. Both assays have been demonstrated in low-throughput format and we will optimize conditions for high throughput screening. We will additionally perform pilot studies to statistically validate the assays with thre commercially available libraries totaling 4400 compounds, which are available at the neighboring Roswell Park Small Molecule Screening Center. Finally, we will develop orthogonal biochemical and whole cell secondary assays that will be used to confirm specificity and remove false positives.